TY - JOUR
T1 - Outcomes of operative treatment for adult spinal deformity
T2 - a prospective multicenter assessment with mean 4-year follow-up
AU - Elias, Elias
AU - Bess, Shay
AU - Line, Breton
AU - Lafage, Virginie
AU - Lafage, Renaud
AU - Klineberg, Eric
AU - Jo Kim, Han
AU - Passias, Peter G.
AU - Nasser, Zeina
AU - Gum, Jeffrey L.
AU - Kebaish, Khal
AU - Eastlack, Robert
AU - Daniels, Alan H.
AU - Mundis, Gregory
AU - Hostin, Richard
AU - Protopsaltis, Themistocles S.
AU - Soroceanu, Alex
AU - Hamilton, D. Kojo
AU - Kelly, Michael P.
AU - Gupta, Munish
AU - Hart, Robert
AU - Schwab, Frank J.
AU - Burton, Douglas
AU - Ames, Christopher P.
AU - Shaffrey, Christopher I.
AU - Smith, Justin S.
N1 - Funding Information:
DePuy Synthes, NuVasive, Stryker, Medtronic, Globus, SeaSpine, Carlsmed, and ISSGF; and receives royalties from Stryker and NuVasive. Dr. Lafage is a consultant for Globus Medical; receives royalties from NuVasive; receives honoraria from DePuy Synthes and Stryker; and owns stock in VFT Solutions. Dr. Klineberg is a consultant for DePuy Synthes, Stryker, and Medicrea/Medtronic; and receives honoraria and a fellowship grant paid to an institution from AO Spine. Dr. Passias is a consultant for Medtronic, Globus, and Royal Biologics. Dr. Gum is an employee of Norton Healthcare, Inc.; is a consultant for Acuity, DePuy, Medtronic, NuVasive, and Stryker; owns stock in Cingulate; holds patents with Medtronic; receives honoraria from Baxter, Broadwater, NASS, and Pacira Pharmaceuticals; is on the speakers bureau of Medtronic and Stryker; receives royalties from Acuity, Medtronic, and NuVasive; serves on the medical scientific board of the National Spine Health Foundation; receives research support from the Alan L. & Jacqueline B. Stuart Spine Center, Cerapedics, Biom’Up, Medtronic, Pfizer, Scoliosis Research Society, TSRH, Empirical Spine, Inc., National Health Foundation, and Stryker; and serves as a journal reviewer for Global Spine Journal, Spine Deformity, and The Spine Journal. Dr. Eastlack owns stock in NuVasive, Alphatec, SI Bone, SeaSpine, and Spine Innovation; is a consultant for NuVasive, SeaSpine, SI Bone, Stryker, Medtronic, Spinal Elements, Biedermann-Motech, and Carevature; holds patents with SI Bone, Spine Innovation, and Globus Medical; receives royalties from NuVasive, SeaSpine, SI Bone, and Globus; and receives non–study-related clinical or research support from NuVasive, Medtronic, SeaSpine, and AONA. Dr. Mundis is a consultant for NuVasive, Stryker, Viseon, Carlsmed, and SeaSpine; holds patents with Stryker; and receives royalties from NuVasive and K2M/Stryker. Dr. Protopsaltis is a consultant for Globus, NuVasive, Stryker K2M, and Medtronic; receives royalties from Altus; receives stock options from Torus Medical; and is a stock option unit holder for Spine Align. Dr. Kelly receives honoraria from Spine and non–study-related clinical or research support from the Setting Scoliosis Straight Foundation. Dr. Gupta owns stock in J&J; is a consultant for DePuy, Medtronic, Globus, and Alphatec (began and ended in 2019); receives royalties from Innomed, DePuy, and Globus; receives honoraria from AO Spine, Wright State, LSU, and the Malaysia Spine Society; serves on the board of directors of the Scoliosis Research Society; receives travel reimbursements from DePuy, Globus, Medtronic, Scoliosis Research Society, Zimmer, and AO Spine; and has a voluntary relationship with the National Spine Health Foundation. Dr. Hart is a consultant for Allosource, Globus, Orthofix, MiRus, DePuy, Medtronic, PropioVision, and SeaSpine; and has a personal relationship with ISSG and Amplify. Dr. Schwab is a consultant for MSD, Zimmer Biomet, and Mainstay Medical; receives royalties from Zimmer Biomet, Medtronic, and Medicrea; owns stock in VFT Solutions and SeaSpine; is an executive committee member of ISSG; and receives non–study-related clinical or research support from DePuy, K2M, NuVasive, Medtronic, Globus, Allosource, Orthofix, and SI Bone (via grants paid through ISSG). Dr. Burton is a consultant for Blue Ocean Spine, Globus, and DePuy; and owns stock in Progenerative Medical. Dr. Ames receives royalties from Stryker, Biomet Zimmer Spine, DePuy Synthes, NuVasive, Next Orthosurgical, K2M, and Medicrea; is a consultant for DePuy Synthes, Medtronic, Medicrea, K2M, Agada Medical, and Carlsmed; receives research support from Titan Spine, DePuy Synthes, and ISSG; serves on the editorial board of Operative Neurosurgery; receives grant funding from SRS; serves on the executive committee of ISSG; is the director of Global Spinal Analytics; and is the safety and value committee chair of SRS. Dr. Shaffrey is a consultant for NuVasive, Medtronic, SI Bone, and Proprio; owns stock in NuVasive; holds patents with NuVasive, Medtronic, and Zimmer Biomet; and receives royalties from NuVasive, Medtronic, and Zimmer Biomet. Dr. Smith is a consultant for Zimmer Biomet, NuVasive, Cerapedics, Carlsmed, Stryker, SeaSpine, and DePuy Synthes; owns stock in Alphatec and NuVasive; receives study-related clinical or research support from DePuy Synthes and ISSGF; receives non–study-related clinical or research support from DePuy Synthes, ISSGF, and AO Spine; receives royalties from Zimmer Biomet, NuVasive, and Thieme; and receives fellowship support from AO Spine.
Publisher Copyright:
© AANS 2022, except where prohibited by US copyright law.
PY - 2022/10
Y1 - 2022/10
N2 - OBJECTIVE The current literature has primarily focused on the 2-year outcomes of operative adult spinal deformity (ASD) treatment. Longer term durability is important given the invasiveness, complications, and costs of these procedures. The aim of this study was to assess minimum 3-year outcomes and complications of ASD surgery. METHODS Operatively treated ASD patients were assessed at baseline, follow-up, and through mailings. Patient-reported outcome measures (PROMs) included scores on the Oswestry Disability Index (ODI), Scoliosis Research Society–22r (SRS-22r) questionnaire, mental component summary (MCS) and physical component summary (PCS) of the SF-36, and numeric rating scale (NRS) for back and leg pain. Complications were classified as perioperative (≤ 90 days), delayed (90 days to 2 years), and long term (≥ 2 years). Analyses focused on patients with minimum 3-year follow-up. RESULTS Of 569 patients, 427 (75%) with minimum 3-year follow-up (mean ± SD [range] 4.1 ± 1.1 [3.0–9.6] years) had a mean age of 60.8 years and 75% were women. Operative treatment included a posterior approach for 426 patients (99%), with a mean ± SD 12 ± 4 fusion levels. Anterior lumbar interbody fusion was performed in 35 (8%) patients, and 89 (21%) underwent 3-column osteotomy. All PROMs improved significantly from baseline to last follow-up, including scores on ODI (45.4 to 30.5), PCS (31.0 to 38.5), MCS (45.3 to 50.6), SRS-22r total (2.7 to 3.6), SRS-22r activity (2.8 to 3.5), SRS-22r pain (2.3 to 3.4), SRS-22r appearance (2.4 to 3.5), SRS-22r mental (3.4 to 3.7), SRS-22r satisfaction (2.7 to 4.1), NRS for back pain (7.1 to 3.8), and NRS for leg pain (4.8 to 3.0) (all p < 0.001). Degradations in some outcome measures were observed between the 2-year and last follow-up evaluations, but the magnitudes of these degradations were modest and arguably not clinically significant. Overall, 277 (65%) patients had at least 1 complication, including 185 (43%) perioperative, 118 (27%) delayed, and 56 (13%) long term. Notably, the 142 patients who did not achieve 3-year follow-up were similar to the study patients in terms of demographic characteristics, deformities, and baseline PROMs and had similar rates and types of complications. CONCLUSIONS This prospective multicenter analysis demonstrated that operative ASD treatment provided significant improvement of health-related quality of life at minimum 3-year follow-up (mean 4.1 years), suggesting that the benefits of surgery for ASD remain durable at longer follow-up. These findings should prove useful for counseling, cost-effectiveness assessments, and efforts to improve the safety of care.
AB - OBJECTIVE The current literature has primarily focused on the 2-year outcomes of operative adult spinal deformity (ASD) treatment. Longer term durability is important given the invasiveness, complications, and costs of these procedures. The aim of this study was to assess minimum 3-year outcomes and complications of ASD surgery. METHODS Operatively treated ASD patients were assessed at baseline, follow-up, and through mailings. Patient-reported outcome measures (PROMs) included scores on the Oswestry Disability Index (ODI), Scoliosis Research Society–22r (SRS-22r) questionnaire, mental component summary (MCS) and physical component summary (PCS) of the SF-36, and numeric rating scale (NRS) for back and leg pain. Complications were classified as perioperative (≤ 90 days), delayed (90 days to 2 years), and long term (≥ 2 years). Analyses focused on patients with minimum 3-year follow-up. RESULTS Of 569 patients, 427 (75%) with minimum 3-year follow-up (mean ± SD [range] 4.1 ± 1.1 [3.0–9.6] years) had a mean age of 60.8 years and 75% were women. Operative treatment included a posterior approach for 426 patients (99%), with a mean ± SD 12 ± 4 fusion levels. Anterior lumbar interbody fusion was performed in 35 (8%) patients, and 89 (21%) underwent 3-column osteotomy. All PROMs improved significantly from baseline to last follow-up, including scores on ODI (45.4 to 30.5), PCS (31.0 to 38.5), MCS (45.3 to 50.6), SRS-22r total (2.7 to 3.6), SRS-22r activity (2.8 to 3.5), SRS-22r pain (2.3 to 3.4), SRS-22r appearance (2.4 to 3.5), SRS-22r mental (3.4 to 3.7), SRS-22r satisfaction (2.7 to 4.1), NRS for back pain (7.1 to 3.8), and NRS for leg pain (4.8 to 3.0) (all p < 0.001). Degradations in some outcome measures were observed between the 2-year and last follow-up evaluations, but the magnitudes of these degradations were modest and arguably not clinically significant. Overall, 277 (65%) patients had at least 1 complication, including 185 (43%) perioperative, 118 (27%) delayed, and 56 (13%) long term. Notably, the 142 patients who did not achieve 3-year follow-up were similar to the study patients in terms of demographic characteristics, deformities, and baseline PROMs and had similar rates and types of complications. CONCLUSIONS This prospective multicenter analysis demonstrated that operative ASD treatment provided significant improvement of health-related quality of life at minimum 3-year follow-up (mean 4.1 years), suggesting that the benefits of surgery for ASD remain durable at longer follow-up. These findings should prove useful for counseling, cost-effectiveness assessments, and efforts to improve the safety of care.
KW - adult spinal deformity
KW - complications
KW - outcomes
KW - prospective multicenter
KW - surgery
UR - http://www.scopus.com/inward/record.url?scp=85139548899&partnerID=8YFLogxK
U2 - 10.3171/2022.3.SPINE2295
DO - 10.3171/2022.3.SPINE2295
M3 - Article
C2 - 35535835
AN - SCOPUS:85139548899
SN - 1547-5654
VL - 37
SP - 607
EP - 616
JO - Journal of Neurosurgery: Spine
JF - Journal of Neurosurgery: Spine
IS - 4
ER -